Blow To AZ As FDA Rejects COPD Contender
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
You may also be interested in...
Glenmark rolls out three-in-one inhaler therapy for COPD in India and hopes to address challenges faced by patients suffering from the severe form of the disease. Some early physician outlook appears mixed for the new combination in a segment where leading respiratory player Cipla has an established product.
A pioneer in the field, can GSK’s investment in real world studies pay off?
The latest drug development news and highlights from our US FDA Performance Tracker.